In this free webinar, learn about parameters that limit the efficacy of current chimeric antigen receptor (CAR) T-cell therapies and enable the development of CAR T-cells with enhanced performance. Attendees will learn how the in vitro acclimation of cancer cells to conditions that resemble the tumor microenvironment results in cell line models with altered characteristics that are similar to animal model studies. The featured speakers will discuss how meaningful new approaches can aid biopharmaceutical companies in developing new and novel cell and gene therapies (CGTs) to enable improved patient outcomes.
TORONTO, Nov. 20, 2024 /PRNewswire-PRWeb/ -- The development and approval of chimeric antigen receptor (CAR) T-cell therapies to treat several B-cell-derived hematologic malignancies has been recognized as a significant advance in clinical treatment.
Solid tumors represent 90 percent of all adult cancers. Therefore, there is an urgent need to tackle current obstacles to cell therapy development in this space. Key challenges include the hostile tumor microenvironment (TME) and a lack of effective cell therapy penetration and persistence in solid tumors.
To address these challenges, methods that can generate more potent cell populations during drug discovery and subsequently translate to the manufacturing process must be investigated. In this webinar, data from a series of projects focused on the improvement of cell and gene therapy (CGT) safety and efficacy are discussed.
A comparison of the phenotype and performance of cancer cell lines and CAR T-cells grown in conventional culture conditions with those grown in conditions that more closely resemble the TME was undertaken using the AVATARTM Odyssey system from Xcell Biosciences (Xcellbio). Cells were cultured and grown under regulated conditions, including modified oxygen and pressure levels, while adhering to established protocols for cell therapy development, with no special techniques needed for cell growth. The resulting cells are thought to undergo metabolic reprogramming, which may increase cell-killing properties and lead to better anti-tumor activity. Data and insights from this work will be shared.
Register for this webinar today to explore cutting-edge advancements in CAR T-cell therapies aimed at overcoming key challenges in treating solid tumors.
Join James Lim, PhD, Chief Scientific Officer, Xcell Biosciences; Ningchun Liu, PhD, Director of Enterprise Cell and Gene Therapy, Labcorp; Anita J. Zaitouna, PhD, Scientist, Scientific Development, Assay Development (Research), Labcorp; Dr. Maryland Franklin, PhD, Vice President and Enterprise Head, Cell and Gene Therapy, Labcorp; and Brian Feth, Co-founder and CEO, Xcell Biosciences, for the live webinar on Wednesday, December 11, 2024, at 1pm EST (10am PST).
For more information, or to register for this event, visit Developing Predictive Cancer Models and More Persistent CAR T-cell Therapies through Enhanced Metabolic Fitness.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article